First Time Loading...

MEI Pharma Inc
NASDAQ:MEIP

Watchlist Manager
MEI Pharma Inc Logo
MEI Pharma Inc
NASDAQ:MEIP
Watchlist
Price: 3.23 USD -0.62% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

MEIP's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. [ Read More ]

The intrinsic value of one MEIP stock under the Base Case scenario is 10.83 USD. Compared to the current market price of 3.23 USD, MEI Pharma Inc is Undervalued by 70%.

Key Points:
MEIP Intrinsic Value
Base Case
10.83 USD
Undervaluation 70%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
MEI Pharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MEIP stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
MEI Pharma Inc

Provide an overview of the primary business activities
of MEI Pharma Inc.

What unique competitive advantages
does MEI Pharma Inc hold over its rivals?

What risks and challenges
does MEI Pharma Inc face in the near future?

Has there been any significant insider trading activity
in MEI Pharma Inc recently?

Summarize the latest earnings call
of MEI Pharma Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MEI Pharma Inc.

Provide P/S
for MEI Pharma Inc.

Provide P/E
for MEI Pharma Inc.

Provide P/OCF
for MEI Pharma Inc.

Provide P/FCFE
for MEI Pharma Inc.

Provide P/B
for MEI Pharma Inc.

Provide EV/S
for MEI Pharma Inc.

Provide EV/GP
for MEI Pharma Inc.

Provide EV/EBITDA
for MEI Pharma Inc.

Provide EV/EBIT
for MEI Pharma Inc.

Provide EV/OCF
for MEI Pharma Inc.

Provide EV/FCFF
for MEI Pharma Inc.

Provide EV/IC
for MEI Pharma Inc.

Show me price targets
for MEI Pharma Inc made by professional analysts.

What are the Revenue projections
for MEI Pharma Inc?

How accurate were the past Revenue estimates
for MEI Pharma Inc?

What are the Net Income projections
for MEI Pharma Inc?

How accurate were the past Net Income estimates
for MEI Pharma Inc?

What are the EPS projections
for MEI Pharma Inc?

How accurate were the past EPS estimates
for MEI Pharma Inc?

What are the EBIT projections
for MEI Pharma Inc?

How accurate were the past EBIT estimates
for MEI Pharma Inc?

Compare the revenue forecasts
for MEI Pharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MEI Pharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MEI Pharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of MEI Pharma Inc compared to its peers.

Compare the P/E ratios
of MEI Pharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing MEI Pharma Inc with its peers.

Analyze the financial leverage
of MEI Pharma Inc compared to its main competitors.

Show all profitability ratios
for MEI Pharma Inc.

Provide ROE
for MEI Pharma Inc.

Provide ROA
for MEI Pharma Inc.

Provide ROIC
for MEI Pharma Inc.

Provide ROCE
for MEI Pharma Inc.

Provide Gross Margin
for MEI Pharma Inc.

Provide Operating Margin
for MEI Pharma Inc.

Provide Net Margin
for MEI Pharma Inc.

Provide FCF Margin
for MEI Pharma Inc.

Show all solvency ratios
for MEI Pharma Inc.

Provide D/E Ratio
for MEI Pharma Inc.

Provide D/A Ratio
for MEI Pharma Inc.

Provide Interest Coverage Ratio
for MEI Pharma Inc.

Provide Altman Z-Score Ratio
for MEI Pharma Inc.

Provide Quick Ratio
for MEI Pharma Inc.

Provide Current Ratio
for MEI Pharma Inc.

Provide Cash Ratio
for MEI Pharma Inc.

What is the historical Revenue growth
over the last 5 years for MEI Pharma Inc?

What is the historical Net Income growth
over the last 5 years for MEI Pharma Inc?

What is the current Free Cash Flow
of MEI Pharma Inc?

Financials

Balance Sheet Decomposition
MEI Pharma Inc

Current Assets 66.2m
Cash & Short-Term Investments 59.5m
Other Current Assets 6.7m
Non-Current Assets 12.4m
PP&E 12.4m
Current Liabilities 8m
Accounts Payable 1.4m
Accrued Liabilities 6.7m
Non-Current Liabilities 11m
Other Non-Current Liabilities 11m
Efficiency

Earnings Waterfall
MEI Pharma Inc

Revenue
72.7m USD
Operating Expenses
-56.8m USD
Operating Income
15.9m USD
Other Expenses
4m USD
Net Income
19.8m USD

Free Cash Flow Analysis
MEI Pharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MEIP Profitability Score
Profitability Due Diligence

MEI Pharma Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

34/100
Profitability
Score

MEI Pharma Inc's profitability score is 34/100. The higher the profitability score, the more profitable the company is.

MEIP Solvency Score
Solvency Due Diligence

MEI Pharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

MEI Pharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MEIP Price Targets Summary
MEI Pharma Inc

Wall Street analysts forecast MEIP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MEIP is 23.46 USD with a low forecast of 7.07 USD and a high forecast of 44.1 USD.

Lowest
Price Target
7.07 USD
119% Upside
Average
Price Target
23.46 USD
626% Upside
Highest
Price Target
44.1 USD
1 265% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MEIP Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MEIP Price
MEI Pharma Inc

1M 1M
-13%
6M 6M
-53%
1Y 1Y
-33%
3Y 3Y
-95%
5Y 5Y
-95%
10Y 10Y
-98%
Annual Price Range
3.23
52w Low
3.2
52w High
7.84
Price Metrics
Average Annual Return -24.11%
Standard Deviation of Annual Returns 46.74%
Max Drawdown -96%
Shares Statistics
Market Capitalization 21.5m USD
Shares Outstanding 6 662 860
Percentage of Shares Shorted 0.14%

MEIP Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

MEI Pharma Inc Logo
MEI Pharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

21.5m USD

Dividend Yield

0%

Description

MEI Pharma, Inc. is a pharmaceutical company, which engages in the clinical development of therapies for cancer. The company is headquartered in San Diego, California and currently employs 76 full-time employees. The company went IPO on 2003-12-18. The firm is focused on development and commercialization of novel cancer therapies. The firm's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the treatment of B-cell malignancies. The firm is conducting Phase II study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (MZL) patients who have received at least two prior lines of treatment. Its Voruciclib an oral cyclin-dependent kinase 9(CDK9) inhibitor for the treatment of myeloid leukemia and B-cell malignancies. Its ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation (OXPHOS). Its Pracinostat is an oral histone deacetylase (HDAC) inhibitor being evaluated in a Phase II trial in patients with high or very high-risk myelodysplastic syndrome (MDS).

Contact

CALIFORNIA
San Diego
11455 El Camino Real, Suite 250
+18583697100.0
https://www.meipharma.com/

IPO

2003-12-18

Employees

76

Officers

CEO, President & Director
Mr. David M. Urso B.A., Esq., J.D.
Chief Medical Officer
Dr. Richard G. Ghalie M.D., MBA
CFO & Corporate Secretary
Mr. Justin J. File
Senior Vice President of Operations & Quality
Ms. Yomara Gomez-Naiden
Vice President of Legal Affairs
Ms. Nicole Chyoko Iida
Chief People Officer
Ms. Anne Frese
Show More
Strategic Advisor
Dr. Robert D. Mass
Senior Vice President of Corporate Affairs
Mr. David A. Walsey J.D., L.L.M.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MEIP stock?

The intrinsic value of one MEIP stock under the Base Case scenario is 10.83 USD.

Is MEIP stock undervalued or overvalued?

Compared to the current market price of 3.23 USD, MEI Pharma Inc is Undervalued by 70%.